Conclusions During lamivudine therapy, there is no relation between the YMDD mutation and the HBV genotypes.
结论拉米夫定治疗期间，HBV的YMDD变异不受病毒基因型的影响。
Objective:To observe the efficacy and safety of adefovir dipivoxil(ADV)for chronic hepatitis B(CHB)with YMDD mutation during lamivudine(LAM)therapy.
目的 系统评价与拉米夫定相关的乙型肝炎病毒YMDD区变异后不同抗病毒治疗方法的疗效和安全性。
Objective:To observe the efficacy and safety of adefovir dipivoxil(ADV)for chronic hepatitis B(CHB)with YMDD mutation during lamivudine(LAM)therapy.
目的 系统评价与拉米夫定相关的乙型肝炎病毒YMDD区变异后不同抗病毒治疗方法的疗效和安全性。
应用推荐